{"id":62808,"date":"2026-03-18T19:02:22","date_gmt":"2026-03-18T18:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/"},"modified":"2026-03-18T19:02:22","modified_gmt":"2026-03-18T18:02:22","slug":"nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/","title":{"rendered":"Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss"},"content":{"rendered":"
\n

\nThe Smart Neurostimulation System is the first neurostimulation device to receive Breakthrough designation for TBI-related memory loss; the implant decodes memory states from neural activity on 60 channels spanning four brain regions and delivers AI-guided personalized stimulation therapy to lateral temporal cortex<\/i><\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

BOSTON–(BUSINESS WIRE)–Nia Therapeutics announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to its Smart Neurostimulation System (SNS) for the treatment of episodic memory loss in adult patients with prior moderate-to-severe traumatic brain injury (TBI) and persistent memory deficits. The SNS is the first device to receive Breakthrough designation for TBI-related memory loss. There is significant unmet need in this indication, with no FDA-cleared or approved therapies to treat memory loss and more than 4.3 million Americans living with TBI-related disability.1<\/sup><\/p>\n

\n\u201cThe Breakthrough designation validates the approach we’ve spent a decade building\u2014that memory can be improved by listening to the brain and stimulating at precisely the right moment,\u201d <\/i>said Michael Kahana, PhD, co-founder and CEO of Nia Therapeutics, and the Edmund and Louise Kahn Term Professor at the University of Pennsylvania. \u201cThis designation provides a framework to work closely with the FDA as we bring this technology from the laboratory into the clinic.\u201d<\/i><\/p>\n

\nA New Approach to Treating Memory Disorders<\/b><\/p>\n

\nThe SNS is a fully implantable, wireless neuromodulation platform that records neural activity from 60 channels across four brain regions. Using machine-learning classifiers trained on each patient\u2019s own brain signals, the device detects moments of impaired memory encoding in real time and delivers targeted electrical stimulation to the lateral temporal cortex. This closed-loop approach improved recall by 19% in a randomized, sham-controlled study of neurosurgical patients with epilepsy and a history of moderate-to-severe TBI.2<\/sup> Randomly timed stimulation produced no benefit, underscoring the importance of delivering therapy at the right moment.3<\/sup><\/p>\n

\n\u201cMemory depends on coordinated activity across widespread brain networks\u2014so we built a device that can sense and respond across the entire network. With 60 channels across four brain regions, the SNS offers an order of magnitude improvement over currently approved DBS devices,<\/i>\u201d<\/i> <\/i>said Daniel Rizzuto, PhD, co-founder and CTO of Nia Therapeutics.<\/p>\n

\nPath Forward<\/b><\/p>\n

\nThe designation provides Nia with prioritized review, increased FDA interaction, and senior management involvement in future submissions. Building on the first in vivo validation of the SNS platform in a large-animal model, published in Brain Stimulation <\/i>in 2026 (link<\/a>), this designation will support the company as it advances toward an Investigational Device Exemption (IDE) application this year to support a first-in-human early feasibility study.<\/p>\n

\n\u201cPatients with TBI-related memory loss represent a profoundly underserved population,\u201d <\/i>said Dr. Ramon Diaz-Arrastia, Presidential Professor of Neurology and Director of the TBI Clinical Research Center at the University of Pennsylvania, and advisor to Nia Therapeutics. \u201cTheir disability is invisible but devastating\u2014it affects the ability to work, maintain relationships, and live independently. We are committed to bringing them the first treatment that directly restores the capacity to form new memories.\u201d<\/i><\/p>\n

\nAbout Nia Therapeutics<\/b><\/p>\n

\nNia Therapeutics develops implantable brain-computer interfaces for memory disorders. Founded in 2018, the company\u2019s SNS platform enables closed-loop neuromodulation by detecting brain states linked to impaired memory encoding and delivering targeted stimulation. Visit www.niatx.com<\/a>.<\/p>\n

\nSources<\/b><\/p>\n

    \n
  1. \nCenter for Disease Control and Prevention. (2015). Report to Congress on traumatic brain injury in the United States: Epidemiology and rehabilitation<\/i> (cdc:29215). https:\/\/stacks.cdc.gov\/view\/cdc\/29215<\/a><\/li>\n
  2. \nKahana, M. J., Ezzyat, Y ., Wanda, P. A., Solomon, E. A., Adamovich-Zeitlin, R., Lega, B. C., Jobst, B. C., Gross, R. E., Ding, K., & Diaz-Arrastia, R. R. (2023). Biomarker-guided neuromodulation aids memory in traumatic brain injury. Brain Stimulation<\/i>, 16<\/i>(4), 1086\u20131093. https:\/\/doi.org\/10.1016\/j.brs.2023.07.002<\/a><\/li>\n
  3. \nEzzyat, Y ., Kragel, J. E., Solomon, E. A., Lega, B. C., Aronson, J. P., Jobst, B. C., Gross, R. E., Sperling, M. R., Worrell, G. A., Sheth, S. A., Wanda, P. A., Rizzuto, D. S., & Kahana, M. J. (2024). Functional and anatomical connectivity predict brain stimulation\u2019s mnemonic effects. Cerebral Cortex<\/i>, 34<\/i>(1), bhad427. https:\/\/doi.org\/10.1093\/cercor\/bhad427<\/a><\/li>\n<\/ol>\n

    Contacts<\/b> <\/p>\n

    \nFor media inquiries, contact media<\/a>@niatx.com<\/a>.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    The Smart Neurostimulation System is the first neurostimulation device to receive Breakthrough designation for TBI-related memory loss; the implant decodes memory states from neural activity on 60 channels spanning four brain regions and delivers AI-guided personalized stimulation therapy to lateral temporal cortex BOSTON–(BUSINESS WIRE)–Nia Therapeutics announced that the U.S. Food and Drug Administration has granted … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62808","6":"format-standard","7":"category-industry"},"yoast_head":"\nNia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The Smart Neurostimulation System is the first neurostimulation device to receive Breakthrough designation for TBI-related memory loss; the implant decodes memory states from neural activity on 60 channels spanning four brain regions and delivers AI-guided personalized stimulation therapy to lateral temporal cortex BOSTON–(BUSINESS WIRE)–Nia Therapeutics announced that the U.S. Food and Drug Administration has granted ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T18:02:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260313678930\/en\/2746842\/22\/7_NiaTherapeutics_0350_free.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss\",\"datePublished\":\"2026-03-18T18:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/\"},\"wordCount\":676,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260313678930\\\/en\\\/2746842\\\/22\\\/7_NiaTherapeutics_0350_free.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/\",\"name\":\"Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260313678930\\\/en\\\/2746842\\\/22\\\/7_NiaTherapeutics_0350_free.jpg\",\"datePublished\":\"2026-03-18T18:02:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260313678930\\\/en\\\/2746842\\\/22\\\/7_NiaTherapeutics_0350_free.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260313678930\\\/en\\\/2746842\\\/22\\\/7_NiaTherapeutics_0350_free.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/","og_locale":"en_US","og_type":"article","og_title":"Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss - Pharma Trend","og_description":"The Smart Neurostimulation System is the first neurostimulation device to receive Breakthrough designation for TBI-related memory loss; the implant decodes memory states from neural activity on 60 channels spanning four brain regions and delivers AI-guided personalized stimulation therapy to lateral temporal cortex BOSTON–(BUSINESS WIRE)–Nia Therapeutics announced that the U.S. Food and Drug Administration has granted ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-18T18:02:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260313678930\/en\/2746842\/22\/7_NiaTherapeutics_0350_free.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss","datePublished":"2026-03-18T18:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/"},"wordCount":676,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260313678930\/en\/2746842\/22\/7_NiaTherapeutics_0350_free.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/","url":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/","name":"Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260313678930\/en\/2746842\/22\/7_NiaTherapeutics_0350_free.jpg","datePublished":"2026-03-18T18:02:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260313678930\/en\/2746842\/22\/7_NiaTherapeutics_0350_free.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260313678930\/en\/2746842\/22\/7_NiaTherapeutics_0350_free.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-memory-loss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62808"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62808\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}